Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margalida Rotger

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
European Journal of Clinical Pharmacology|January 12, 2008
Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?Margalida Rotger, Amalio Telenti
Frontiers in Pharmacology|January 26, 2012
Pharmacogenomics: what is next?Julia di Iulio, Margalida Rotger
Current HIV/AIDS Reports|September 15, 2006
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agentsMargalida Rotger, Chantal Csajka, Amalio Telenti
Enfermedades Infecciosas Y Microbiologia Clinica|December 17, 2008
[General concepts and study methods in pharmacogenetics]Rubin Lubomirov, Amalio Telenti, Margalida Rotger
Pharmacogenomics|March 31, 2010
Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomicsPhilip E Tarr, Margalida Rotger, Amalio Telenti
Journal of Clinical Microbiology|August 6, 2005
Phenotypic and genotypic mupirocin resistance among Staphylococci causing prosthetic joint infectionMargalida Rotger, Andrej Trampuz, Kerryl E Piper, et al.
Antiviral Therapy|May 17, 2007
Does tenofovir influence efavirenz pharmacokinetics?Margalida Rotger, Sara Colombo, Hansjakob Furrer, et al.
Pharmacogenetics and Genomics|September 22, 2007
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7Margalida Rotger, Maria Saumoy, Kunlin Zhang, et al.
Antiviral Therapy|May 4, 2013
Efavirenz intoxication due to a new CYP2B6 constellationAlexia Anagnostopoulos, Margalida Rotger, Manel Aouri, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureusMark S Rouse, Margalida Rotger, Kerryl E Piper, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
European Journal of Clinical Pharmacology|January 12, 2008
Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?Margalida Rotger, Amalio Telenti
Frontiers in Pharmacology|January 26, 2012
Pharmacogenomics: what is next?Julia di Iulio, Margalida Rotger
Current HIV/AIDS Reports|September 15, 2006
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agentsMargalida Rotger, Chantal Csajka, Amalio Telenti
Enfermedades Infecciosas Y Microbiologia Clinica|December 17, 2008
[General concepts and study methods in pharmacogenetics]Rubin Lubomirov, Amalio Telenti, Margalida Rotger
Pharmacogenomics|March 31, 2010
Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomicsPhilip E Tarr, Margalida Rotger, Amalio Telenti
Journal of Clinical Microbiology|August 6, 2005
Phenotypic and genotypic mupirocin resistance among Staphylococci causing prosthetic joint infectionMargalida Rotger, Andrej Trampuz, Kerryl E Piper, et al.
Antiviral Therapy|May 17, 2007
Does tenofovir influence efavirenz pharmacokinetics?Margalida Rotger, Sara Colombo, Hansjakob Furrer, et al.
Pharmacogenetics and Genomics|September 22, 2007
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7Margalida Rotger, Maria Saumoy, Kunlin Zhang, et al.
Antiviral Therapy|May 4, 2013
Efavirenz intoxication due to a new CYP2B6 constellationAlexia Anagnostopoulos, Margalida Rotger, Manel Aouri, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureusMark S Rouse, Margalida Rotger, Kerryl E Piper, et al.
Pageof 5